Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review

JAMA - Journal of the American Medical Association

Volumn 313, Issue 24, 2015, Pages 2474-2483

  Hill, Kevin P ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DIHYDROCODEINE; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARNOLD CHIARI MALFORMATION; ARTHRITIS; CACHEXIA; CERVICAL DYSTONIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC PAIN; CHRONIC PANCREATITIS; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; COMPLEX REGIONAL PAIN SYNDROME TYPE II; COORDINATION DISORDER; CROHN DISEASE; DECISION MAKING; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; DYSTONIA; EPILEPSY; FIBROMYALGIA; FIBROUS DYSPLASIA; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HEALTH HAZARD; HEPATITIS C; HUMAN; HUNTINGTON CHOREA; HYDROCEPHALUS; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL CYSTITIS; INTRAOCULAR PRESSURE ABNORMALITY; LIMB PAIN; LOW BACK PAIN; LUPUS VULGARIS; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCULAR DYSTROPHY; MYASTHENIA GRAVIS; MYOCLONUS; NAIL PATELLA SYNDROME; NAUSEA; NEOPLASM; NEUROFIBROMATOSIS; NEUROPATHIC PAIN; PARKINSON DISEASE; PATIENT ASSESSMENT; PATIENT EDUCATION; POSTCONCUSSION SYNDROME; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SPASTICITY; SPINAL CORD DISEASE; SPINAL CORD INJURY; SPINOCEREBELLAR DEGENERATION; SYRINGOMYELIA; TARLOV CYST; TERMINAL DISEASE; TRAUMATIC BRAIN INJURY; WASTING SYNDROME; CASE REPORT; COMPLICATION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; INSURANCE; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEURALGIA; UNITED STATES;

CANNABINOIDS; CHRONIC PAIN; DRUG APPROVAL; HUMANS; INSURANCE COVERAGE; MALE; MEDICAL MARIJUANA; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEURALGIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATE GOVERNMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84937604925     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6199     Document Type: Review

References (69)

1. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.
2. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids. 2010;5(special issue):1-21.
3. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563.
4. Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-1092.
5. ProCon.org. 23 Legal Medical Marijuana States and DC-Medical Marijuana. January 8, 2015. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Accessed March 30, 2015.
6. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
7. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2012. Ann Arbor: Institute for Social Research, University of Michigan; 2013.
8. Hill KP. Medical marijuana: more questions than answers. J Psychiatr Pract. 2014;20(5):389-391.
9. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(suppl 1):S163-S171.
10. Joy JE, Watson SR Jr, Benson JA Jr, eds. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press; 1999.
11. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005;168(168):1-51.
12. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-774.
13. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
14. Marinol [product information]. Marietta, GA: Solvay Pharmaceuticals; 2008.
15. Cesamet [product information]. Aliso Viejo, CA: Valeant Pharmaceuticals, 2008.
16. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164-173.
17. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254-264.
18. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336(7637):199-201.
19. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial [in German]. Wien Klin Wochenschr. 2006;118(11-12):327-335.
20. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253(10):1337-1341.
21. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50-52.
22. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-680.
23. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.
24. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506-521.
25. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain.2007;133(1-3):210-220.
26. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299-306.
27. Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517-1526.
28. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636-641.
29. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125-1132.
30. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41-47.
31. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290-296.
32. Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349-1359.
33. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-424.
34. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987;7(1):39-50.
35. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.
36. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
37. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62(7):1105-1109.
38. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? a double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434-441.
39. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404-1407.
40. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245-1250.
41. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.
42. Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81(10):1135-1140.
43. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17(1):21-29.
44. OCEBM Levels of Evidence Working Group. OCEBM levels of evidence. http://www.cebm.net/ocebm-levels-of-evidence/. Accessed November 1, 2014.
45. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227.
46. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013;59(3):478-492.
47. Smith MJ, Cobia DJ, Wang L, et al. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. Schizophr Bull. 2014;40(2):287-299.
48. Gilman JM, Kuster JK, Lee S, et al. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci. 2014;34(16):5529-5538.
49. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657-E2664.
50. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-130.
51. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-1391.
52. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195-1198.
53. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
54. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence.Hum Psychopharmacol. 2009;24(7):515-523.
55. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003;98(11):1493-1504.
56. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-328.
57. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study [published online February 18, 2015]. Lancet Psychiatry. doi: 10.1016/S2215-0366(14)00117-5.
58. Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969-976.
59. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction. 2000;95(11):1621-1630.
60. Brook JS, Lee JY, Finch SJ, Seltzer N, Brook DW. Adult work commitment, financial stability, and social environment as related to trajectories of marijuana use beginning in adolescence. Subst Abus. 2013;34(3):298-305.
61. th ed. Washington, DC: American Psychiatric Association; 2013.
62. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187-190.
63. Kleber HD, DuPont RL. Physicians and medical marijuana. Am J Psychiatry. 2012;169(6):564-568.
64. Controlled Substances Act, 21 USC §812.
65. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-106.
66. Massachusetts Executive Office of Health and Human Services. Medical marijuana: information for physicians. http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/medical-marijuana/info-for-physicians.html. Accessed August 9, 2014.
67. Programme on Substance Abuse. Cannabis: A Health Perspective and Research Agenda. Geneva, Switzerland: World Health Organization; 1997.
68. Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. JAMA. 2014;311(23):2377-2378.
69. Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: rational guidelines on trial in Washington State. MedGenMed.2007;9(3):52.